Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) – Equities researchers at Wedbush issued their Q1 2023 EPS estimates for shares of Compass Therapeutics in a note issued to investors on Wednesday, March 15th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($0.12) per share for the quarter. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.47) per share. Wedbush also issued estimates for Compass Therapeutics’ Q2 2023 earnings at ($0.13) EPS, Q3 2023 earnings at ($0.14) EPS and Q4 2023 earnings at ($0.15) EPS.
Several other equities research analysts have also recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Thursday. Jefferies Financial Group started coverage on shares of Compass Therapeutics in a research note on Tuesday, January 31st. They issued a “buy” rating and a $8.00 price target for the company. Stifel Nicolaus assumed coverage on Compass Therapeutics in a research note on Thursday, January 26th. They issued a “buy” rating and a $9.00 target price for the company. Finally, EF Hutton Acquisition Co. I initiated coverage on Compass Therapeutics in a research report on Friday, December 16th. They set a “buy” rating and a $10.30 target price on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $9.05.
Compass Therapeutics Price Performance
Insider Activity at Compass Therapeutics
In related news, CEO Thomas J. Schuetz bought 20,000 shares of the company’s stock in a transaction on Tuesday, January 31st. The shares were purchased at an average price of $4.05 per share, for a total transaction of $81,000.00. Following the completion of the transaction, the chief executive officer now directly owns 5,471,873 shares in the company, valued at approximately $22,161,085.65. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, CEO Thomas J. Schuetz acquired 10,000 shares of the stock in a transaction on Friday, March 10th. The stock was purchased at an average price of $3.37 per share, for a total transaction of $33,700.00. Following the completion of the transaction, the chief executive officer now owns 6,021,873 shares of the company’s stock, valued at approximately $20,293,712.01. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Thomas J. Schuetz acquired 20,000 shares of the business’s stock in a transaction dated Tuesday, January 31st. The stock was acquired at an average price of $4.05 per share, for a total transaction of $81,000.00. Following the completion of the transaction, the chief executive officer now owns 5,471,873 shares in the company, valued at approximately $22,161,085.65. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 90,000 shares of company stock worth $355,300. Insiders own 29.80% of the company’s stock.
Institutional Trading of Compass Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in CMPX. Jane Street Group LLC bought a new stake in Compass Therapeutics during the third quarter valued at about $33,000. Bank of New York Mellon Corp purchased a new position in Compass Therapeutics during the third quarter worth $55,000. UBS Group AG increased its position in Compass Therapeutics by 63.5% during the fourth quarter. UBS Group AG now owns 11,819 shares of the company’s stock valued at $59,000 after acquiring an additional 4,591 shares during the last quarter. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Compass Therapeutics in the fourth quarter valued at $75,000. Finally, Boothbay Fund Management LLC bought a new stake in Compass Therapeutics in the fourth quarter worth about $86,000. Hedge funds and other institutional investors own 54.27% of the company’s stock.
Compass Therapeutics Company Profile
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.
- Get a free copy of the StockNews.com research report on Compass Therapeutics (CMPX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.